Dare Bioscience (DARE)
Nasdaq Market Closed
Dare Bioscience, Inc. is a biopharmaceutical company focused exclusively on women’s health, an area that includes contraception, fertility, vaginal health, and sexual wellness. The company develops and acquires product candidates that address conditions where treatment choices can be limited, inconvenient, or poorly suited to patients’ needs. Its strategy is to build a portfolio of differentiated therapies rather than depend on a single scientific platform.
Dare’s first approved product is XACIATO, a prescription clindamycin phosphate vaginal gel used as a single-dose treatment for bacterial vaginosis in females aged 12 years and older. Bacterial vaginosis is one of the most common vaginal infections, and XACIATO gives the company a commercial foothold in a sizeable women’s health market.
The company’s clinical pipeline includes Ovaprene, an investigational hormone-free monthly intravaginal contraceptive designed to provide an alternative to daily pills, long-acting hormonal methods, and barrier products. Another key candidate is Sildenafil Cream, a topical formulation being studied for female sexual arousal disorder. These programmes reflect Dare’s emphasis on products that may improve convenience, tolerability, or patient choice.
As a listed biotechnology stock, Dare is shaped by the typical dynamics of drug development, including clinical trial results, regulatory reviews, partnering arrangements, and access to capital. Its investment profile is therefore closely tied to the progress of its women’s health portfolio and its ability to convert approved or late-stage assets into sustainable commercial revenue.
Last updated
- Market Cap
- 30.71M
- P/E
- —
- P/FCF
- —
- P/S
- 26.54
- Enterprise Value
- 12.79M
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Address
- 3655 NOBEL DRIVE, SAN DIEGO, CA, 92122
UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar
Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
Dare Bioscience regains Nasdaq compliance with bid price - Investing.com
Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule - GlobeNewswire
Daré Bioscience Announces Reverse Stock Split
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024
Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024
Daré Bioscience Announces Executive Team and Board of Directors Changes
Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases
Daré Bioscience Secures $12 million in Royalty-backed Investment Structure
Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study
Daré Bioscience Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1, a Novel Intravaginal Formulation of Tamoxifen for Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy Associated with Menopause
Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program
Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates
Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update
Daré Bioscience Announces Publication in The Journal of The North American Menopause Society of Positive Efficacy Findings for the Treatment of Menopausal Symptoms from a Phase 1/2 Clinical Trial of DARE-HRT1 Intravaginal Rings
Daré Bioscience to Host Second Quarter 2023 Financial Results and Company Update Conference Call and Webcast on August 10, 2023
Daré Bioscience to Present at the 9th Annual International Symposium of Drug Delivery Systems
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 30.71M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 12.79M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 41.81
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 26.54
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -1.29
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 11.05
- EPS
- -0.8
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -10.16M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -1,636.71%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -43.2%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0.81
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 1.03
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 1.03
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.88
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 664.96K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 2.05
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 152.46K | 1.02M | 2.26K | -21.17K | 25.43K |
| Gross profit | -89.87K | 727.88K | 2.26K | -21.17K | 25.43K |
| Operating income | -3M | -1.47M | -3.67M | -3.83M | -4.58M |
| EBITDA | -2.44M | -936.87K | -3.19M | -3.37M | -4.41M |
| Net income | -3M | -1.44M | -3.56M | -4.02M | -4.38M |
| Basic EPS | -0.21 | -0.02 | -0.28 | -0.45 | -0.5 |
| Diluted EPS | -0.21 | -0.02 | -0.28 | -0.45 | -0.5 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 27.83M | 32.47M | 30.75M | 12.98M | 18.62M |
| Total liabilities | 27.09M | 29.63M | 27.89M | 25.71M | 28.18M |
| Total equity | 734.45K | 2.84M | 2.86M | -12.73M | -9.56M |
| Cash & equivalents | 18.52M | 24.71M | 23.08M | 5.04M | 10.33M |
| Current assets | 21.66M | 27.06M | 25M | 6.6M | 11.82M |
| Current liabilities | 21.12M | 23.69M | 21.22M | 19.22M | 21.19M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -5.52M | 1.44M | -442.14K | -5.42M | -5.47M |
| Investing cash flow | — | -206.64K | -174.7K | 153.4K | -157.33K |
| Financing cash flow | -715.47K | 424.13K | 18.65M | -43.79K | 246.58K |
| Change in cash | -6.19M | 1.64M | 18.04M | -5.29M | -5.37M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | DEFA14A — Dare Bioscience, Inc. | View Filing | |
| edgar index | DEFA14A — Dare Bioscience, Inc. | View Filing | |
| edgar index | 8-K — Dare Bioscience, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 253G2 — Dare Bioscience, Inc. | View Filing | |
| edgar index | 8-K — Dare Bioscience, Inc. | View Filing | |
| edgar index | 10-Q — Dare Bioscience, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Dare Bioscience, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | DEF 14A — Dare Bioscience, Inc. | View Filing | |
| edgar index | DEFA14A — Dare Bioscience, Inc. | View Filing | |
| edgar index | ARS — Dare Bioscience, Inc. | View Filing | |
| edgar index | 8-K — Dare Bioscience, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Dare Bioscience, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | PRE 14A — Dare Bioscience, Inc. | View Filing | |
| edgar index | 8-K — Dare Bioscience, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Dare Bioscience, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | QUALIF — Dare Bioscience, Inc. | View Filing | |
| edgar index | 253G2 — Dare Bioscience, Inc. | View Filing | |
| edgar index | 1-A POS — Dare Bioscience, Inc. | View Filing | |
| edgar index | 10-K — Dare Bioscience, Inc. | View Filing | |
| edgar index | 8-K — Dare Bioscience, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 8-K — Dare Bioscience, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Dare Bioscience, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Dare Bioscience, Inc. | View Filing | |
| edgar index | 4 — Dare Bioscience, Inc. | View Filing | |
| form 4 | Form 4 — JOHNSON SABRINA MARTUCCI | View Filing | |
| form 4 | Form 4 — JOHNSON SABRINA MARTUCCI | View Filing | |
| edgar index | 4 — Dare Bioscience, Inc. | View Filing | |
| edgar index | 4 — Dare Bioscience, Inc. | View Filing | |
| form 4 | Form 4 — JOHNSON SABRINA MARTUCCI | View Filing | |
| form 4 | Form 4 — Haring-Layton MarDee | View Filing | |
| edgar index | 8-K — Dare Bioscience, Inc. | View Filing | |
| edgar index | 253G1 — Dare Bioscience, Inc. | View Filing | |
| edgar index | 8-K — Dare Bioscience, Inc. | View Filing | |
| edgar index | QUALIF — Dare Bioscience, Inc. | View Filing | |
| edgar index | 1-A/A — Dare Bioscience, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Dare Bioscience, Inc. | View Filing | |
| edgar index | 8-K — Dare Bioscience, Inc. | View Filing | |
| edgar index | 1-A — Dare Bioscience, Inc. | View Filing | |
| edgar index | 10-Q — Dare Bioscience, Inc. | View Filing | |
| edgar index | 8-K — Dare Bioscience, Inc. | View Filing | |
| edgar index | SCHEDULE 13G — Dare Bioscience, Inc. | View Filing | |
| edgar index | 4 — Dare Bioscience, Inc. | View Filing | |
| form 4 | Form 4 — Haring-Layton MarDee | View Filing | |
| edgar index | 8-K — Dare Bioscience, Inc. | View Filing | |
| edgar index | 10-Q — Dare Bioscience, Inc. | View Filing | |
| edgar index | S-8 — Dare Bioscience, Inc. | View Filing | |
| edgar index | 8-K — Dare Bioscience, Inc. | View Filing | |
| edgar index | 8-K — Dare Bioscience, Inc. | View Filing | |
| edgar index | 8-K — Dare Bioscience, Inc. | View Filing | |
| edgar index | 8-K — Dare Bioscience, Inc. | View Filing | |
| edgar index | 4 — Dare Bioscience, Inc. | View Filing | |
| edgar index | 4 — Dare Bioscience, Inc. | View Filing | |
| edgar index | 4 — Dare Bioscience, Inc. | View Filing | |
| edgar index | 4 — Dare Bioscience, Inc. | View Filing | |
| edgar index | 4 — Dare Bioscience, Inc. | View Filing | |
| edgar index | 8-K — Dare Bioscience, Inc. | View Filing | |
| form 4 | Form 4 — Kelley Susan L. | View Filing | |
| form 4 | Form 4 — Grossman Jessica D. | View Filing | |
| form 4 | Form 4 — Matz Gregory W | View Filing | |
| form 4 | Form 4 — Steele Robin Joan | View Filing | |
| form 4 | Form 4 — RASTETTER WILLIAM H | View Filing | |
| edgar index | 8-K — Dare Bioscience, Inc. | View Filing |